CLOBETASOL PROPIONATE

  • alembic gets usfda nod for ointment to treat skin disease

    Alembic gets USFDA nod for ointment to treat skin disease

    The approval by the US Food and Drug Administration (USFDA) is for Clobetasol Propionate topical solution USP, 0.05 per cent, which is therapeutically equivalent to the reference listed drug product Temovate Topical Solution, 0.05 per cent, of Fougera Pharmaceuticals Inc.

Join the community of 2M+ industry professionals

Subscribe to our Daily Newsletter

By continuing you agree to our Privacy Policy & Terms & Conditions

Scan to download App

Download ETHealthworld App for Realtime updates of content you follow

  • Seamless reading experience
  • Save your favourite articles
Advertisement
Advertisement